Rubric Capital Management (New York)’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
CP
Rubric Capital Management (New York)'s ADMA Position: Q2 2026 in Review
Rubric Capital Management (New York) increased its ADMA Biologics (ADMA) stake by 416% in Q2 2026, buying an estimated $68.6M and bringing the position to 9,339,414 shares worth $78.2M. The position accounts for 0.72% of the portfolio, ranked #38.
Rubric Capital Management (New York) first reported a position in ADMA in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.
- Rubric Capital Management (New York) held 9,339,414 shares of ADMA Biologics worth $78.2M as of Q2 2026.
- Rubric Capital Management (New York) bought 7,530,006 ADMA Biologics shares in Q2 2026, an estimated $68.6M.
- ADMA Biologics made up 0.72% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #38 holding.
- Rubric Capital Management (New York) first reported a position in ADMA Biologics in Q1 2026 and has held it in 2 quarters since.
- 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.
Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.